Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT02262000
Official study title

Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer

Study summary

This study will help researchers learn about the best dose of radiation to be used when treating large early stage non-small cell lung cancer (NSCLC) with a treatment called stereotactic ablative radiotherapy (SABR). Current treatments with SABR for early stage NSCLC show positive response. But, for large early stage NSCLC it may be better to give different SABR doses than what is used in routine early stage NSCLC treatment. It is not understood which dose is best for treating large early stage NSCLC. Therefore, this study can help researchers learn if giving a higher dose using SABR over a period of 5-10 treatment days can increase the chance of cure for large early stage NSCLC.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedImage Guided Stereotactic Ablative Radiotherapy

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 22, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?West Virginia University

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
West Virginia University
Interventions being studied
Radiation: Image Guided Stereotactic Ablative Radiotherapy
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Early-stage or resectable→
Treatment approach
Radiation therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Non-Small Cell Lung Cancer
  • T2N0M0 or T3(PL3)N0M0 or Locally recurrent ≤ 7 cm
  • Surgically inoperable
  • ECOG Performance 0-2
Reasons someone may not be able to joinExclusion criteria
  • Pacemaker on the same side of the tumor
  • Pregnant
  • Infection that requires IV antibiotics
  • Concomitant or adjuvant anti-neoplastic chemotherapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • West Virginia University Hospitals Mary Babb Randolph Cancer CenterMorgantown, West Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 22, 2021. Always confirm current availability with the study team.

View original record ↗